On Monday, Rapport Therapeutics' Director, James Healy, made a $1.08M buy of RAPP, purchasing 44,032 shares at a cost of $24.52 each. Investors can bag RAPP even cheaper than Healy did, with the stock trading as low as $22.94 in trading on Friday -- that's 6.4% under Healy's purchase price. Rapport Therapeutics is trading up about 1.5% on the day Friday. This buy marks the first one filed by Healy in the past twelve months.
And on Tuesday, Stuart M. Grant bought $1M worth of Eyenovia, buying 1,515,151 shares at a cost of $0.66 a piece. Before this latest buy, Grant bought EYEN on 4 other occasions during the past year, for a total investment of $318,326 at an average of $1.35 per share. Eyenovia is trading up about 10.4% on the day Friday. So far Grant is in the green, up about 28.5% on their buy based on today's trading high of $0.85.
VIDEO: Friday 7/5 Insider Buying Report: RAPP, EYEN
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
